q&more
My watch list
my.chemie.de  
Login  

News

Cancer: Inactive receptor renders immunotherapies ineffective

Important reason for poor response to checkpoint inhibitors identified

Andreas Heddergott / TUM

Patients respond much better to immunotherapies based on checkpoint inhibitors when receptor protein RIG-I is active in cancer cells. This was shown lately by a team surrounding PD Dr. Simon Heidegger (right) and PD Dr. Hendrik Poeck (left).

16-Oct-2019: The aim of immunotherapies is to enable the immune system once again to fight cancer on its own. Drugs known as checkpoint inhibitors are already in clinical use for this purpose. However, they are only effective in about one third of patients. Based on analysis of human tissue samples, a team from the Technical University of Munich (TUM) has now discovered one reason why this is so: an inactive receptor in cancer cells prevents the drugs from reactivating the immune system.

An overactive immune system can be nearly as dangerous as an inactive one, triggering inflammation that attacks the body’s own tissues. To counter this, the immune system has what are known as checkpoint molecules, which, when switched on, act like a brake on the immune system. However, cancer cells can exploit this mechanism: by switching on their checkpoint molecules, they are able to elude attacks by the immune system. The weakened immune response that results is then no longer robust enough to fight off the cancer cells.

A new approach to cancer therapy therefore involves the use of drugs known as checkpoint inhibitors. These substances release the “brake” applied by cancer cells, thus restoring the immune system’s ability to combat cancer. Checkpoint inhibitors are already being used successfully in skin cancer and many other malignancies.

The RIG-I receptor is a key factor

“Unfortunately, checkpoint inhibitors aren’t effective in all patients. Thanks to our recent study, we now understand why that is the case in some forms of cancer, and using experimental approaches, we have even been able to reverse the situation,” says Dr. Simon Heidegger, researcher in Medical Unit III at TUM’s university hospital rechts der Isar and lead author of the paper published in Science Immunology.

RIG-I is a receptor protein that is known to play a role in the body’s defense against viruses. Heidegger and a team headed by his colleague Dr. Hendrik Poeck have now discovered that RIG-I also plays a key role in cancer control. In a number of mouse models for skin, pancreatic and bowel cancer, they showed that mice with cancer cells in which RIG-I is active responded much better to checkpoint inhibitors than mice with RIG-I-inactive cancer cells. Fortunately, a drug already exists that activates RIG-I, and it is already undergoing initial tests in clinical trials with humans. The team has used it successfully in mouse models. Mice that received the drug responded significantly better to treatment with checkpoint inhibitors.

Human skin cancer samples confirm the findings

The team then studied around 450 tissue samples from skin cancer patients to retroactively determine what effect RIG-I activity in the patients’ cancer cells had on their survival. In cases where RIG-I was active, the patients lived significantly longer despite their cancer. The team showed in 20 tested individuals that such patients also responded better to treatment with checkpoint inhibitors.

The researchers now plan to confirm their findings in large-scale trials on patients. “We hope to be able to use RIG-I as a marker as well for predicting how well a patient is likely to respond to therapy. This would avoid unnecessary treatments,” says Heidegger. In addition, they plan to test drugs that activate the RIG-I signal pathway in other mouse models and to investigate the effects of additionally administered checkpoint inhibitors.

Original publication:
S. Heidegger, A. Wintges, F. Stritzke, S. Bek, K. Steiger, P.-A. Koenig, S. Göttert, T. Engleitner, R. Öllinger, T. Nedelko, J. C. Fischer, V. Makarov, C. Winter, R. Rad, M.R.M. van den Brink, J. Ruland, F. Bassermann, T. A. Chan, T. Haas, H. Poeck; "RIG-I activation is critical for responsiveness to checkpoint blockade"; Science Immunology; 2019

Facts, background information, dossiers

  • immunotherapies
  • cancer immunotherapies
  • immune system
  • immune checkpoint i…
  • cancer

More about TU München

  • News

    ClpX-ClpP protein complex could be starting point for new antibiotics

    Antibiotics are still the most important weapon for combatting bacterial infections. But medical science is running out of “ammunition” because of more and more frequently occurring resistances. A research team has now elucidated the structure of the proteolytic complex ClpX-ClpP. This is a ... more

    Light in the nanoworld

    An international team headed up by Alexander Holleitner and Jonathan Finley, physicists at the Technical University of Munich (TUM), has succeeded in placing light sources in atomically thin material layers with an accuracy of just a few nanometers. The new method allows for a multitude of ... more

    Activity of fuel cell catalysts doubled

    An interdisciplinary research team at the Technical University of Munich (TUM) has built platinum nanoparticles for catalysis in fuel cells: The new size-optimized catalysts are twice as good as the best process commercially available today. Fuel cells may well replace batteries as the powe ... more

  • q&more articles

    Diet, gut microbiota and host lipid metabolism

    Nature provides an enormous diversity of lipid molecules that originate from various pathways. Fatty acids are key modules for various lipids, including cell membrane lipids such as phospholipids or triacylglycerols, which are the major components of lipid droplets. Excess lipids or defects ... more

    Translation

    The structure of the big chemical and pharmaceutical companies has changed. Traditional centralised research departments conducting fundamental research have fallen victim to economic considerations. In exchange, young, dynamic start-up enterprises are increasingly brightening up the scene. ... more

  • Authors

    Dr. Josef Ecker

    Josef Ecker, born in 1978, studied biology at the University of Regensburg. He earned his doctorate in 2007, after which he researched as a postdoc at the University Hospital in Regensburg at the Institute of Clinical Chemistry. After several subsequent years in industry, working in executi ... more

    Prof. Dr. Arne Skerra

    Arne Skerra, born in 1961, studied chemistry at the Technical University of Darmstadt and obtained his doctoral degree as Dr. rer. nat. at the Gene Center of the Ludwig-Maximilians Univer­sity Munich in 1989. After staying at the MRC Laboratory of Molecular Biology in Cambridge, UK, and the ... more

    Dr. Thomas Letzel

    Thomas Letzel, born 1970, studied chemistry (1992–1998) at the TU Muenchen and the LMU Muenchen. He acquired his doctorate in 2001 with an environmental-analytical subject at the TU Muenchen, followed by a two years' postdoc stay at the Vrijen Universiteit Amsterdam. He qualified as a profe ... more

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:

 

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE